Frontiers in Immunology (Mar 2024)

Exploring secretory proteome and cytokine kinetic of human peripheral blood mononuclear cells exposed to methicillin-resistant Staphylococcus aureus biofilms and planktonic bacteria

  • Reza Gheitasi,
  • Daniela Röll,
  • Mario M. Müller,
  • Mario M. Müller,
  • Mohadeseh Naseri,
  • Rainer König,
  • Rainer König,
  • Hortense Slevogt,
  • Hortense Slevogt,
  • Mathias W. Pletz,
  • Mathias W. Pletz,
  • Mathias W. Pletz,
  • Oliwia Makarewicz,
  • Oliwia Makarewicz

DOI
https://doi.org/10.3389/fimmu.2024.1334616
Journal volume & issue
Vol. 15

Abstract

Read online

Staphylococcus aureus is a highly successful pathogen infecting various body parts and forming biofilms on natural and artificial surfaces resulting in difficult-to-treat and chronic infections. We investigated the secreted cytokines and proteomes of isolated peripheral blood mononuclear cells (PBMCs) from healthy volunteers exposed to methicillin-resistant S. aureus (MRSA) biofilms or planktonic bacteria. Additionally, the cytokine profiles in sera from patients with community-acquired pneumonia (CAP) caused by S. aureus were investigated. The aim was to gain insights into the immune response involved and differentiate between the planktonic and sessile MRSA forms. We identified 321 and 298 targets that were significantly differently expressed in PBMCs when exposed to planktonic or biofilm-embedded bacteria, respectively. PBMCs exposed to planktonic MRSA cells secreted increased levels of TNF-α, while IL-18 was elevated when exposed to the biofilm. The machine-learning analyses of the cytokine profiles obtained for the in vitro PBMCs and CAP sera distinguished between the two types of bacteria forms based on cytokines IL-18, IL12, and IL-17, and with a lower importance IL-6. Particularly, IL-18 which has not been correlated with S. aureus biofilms so far might represent a suitable marker for monitoring chronification during MRSA infection to individualize the therapy, but this hypothesis must be proved in clinical trials.

Keywords